Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m).
Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
As per the deal, Glenmark Pharma is selling the stake in the life sciences unit for Rs615 for each share.
Following the divestiture, Glenmark Pharma will own a 7.84% stake in GLS.
Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said: “We are pleased to announce this strategic transaction with Nirma, which marks a significant milestone in shaping an independent growth trajectory for GLS.
“This deal aligns with our strategic intent of moving up the value chain to become an innovative/brand-led organisation, with continuous focus on our core therapeutic areas of dermatology, respiratory and oncology.
“It also presents an opportunity for us to strengthen shareholder value through deleveraging and enhancing our overall return profile.”
The conclusion of the deal is subject to necessary closing conditions and approvals from shareholders and regulators.
Following the deal closing, GLS will work as an independent API company under Nirma.
Furthermore, Nirma will make a compulsory open offer to all GLS public shareholders.
Glenmark Pharma continues to maintain growth across all its crucial markets while focusing on return ratios, eventually generating value for the shareholders of the company.
Kotak Investment Banking served as the exclusive financial adviser for Glenmark Pharma and GLS.
S&R Associates and Trilegal were the legal advisers to Glenmark Pharma and GLS, respectively.
Source: pharmaceutical-technology.com
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have said they expect to close before year-end—just received a major vote of confidence from antitrust officials overseas.
With EuroAPI’s restructuring plan underway, the Sanofi spinoff has pulled a new CEO from within its ranks to guide the company’s next chapter. Drug ingredients specialist EuroAPI on Monday said it had accepted the resignations of Ludwig de Mot as CEO and Viviane Monges as chair of the manufacturer’s board.
During an investor update Thursday, Lonza unveiled its “One Lonza” restructuring strategy, under which the company will reorganize its CDMO business, reshape its operating model, work to “elevate” manufacturing and engineering and expand its production footprint.
